EpiCor PET (Fermentate derived from Saccharomyces cerevisiae)

EpiCor PET is a whole-food fermentate derived from Saccharomyces cerevisiae yeast, containing beta-glucans, mannan oligosaccharides, nucleotides, and antioxidants that modulate gut immunity and microbiome composition. It acts primarily by strengthening intestinal tight junctions, reducing intestinal permeability, and acting as a prebiotic substrate to support beneficial bacterial populations in companion animals.

Origin & History

EpiCor PET is a branded dried yeast fermentate (postbiotic) derived from a proprietary fermentation process using the yeast Saccharomyces cerevisiae. It is produced by fermenting whole-cell yeast under specific conditions to generate a complex mixture of metabolites, cell wall components, and microbial byproducts, followed by drying without extraction of specific compounds.

Historical & Cultural Context

No historical or traditional medicinal use has been identified for EpiCor. It is a modern branded postbiotic developed through commercial fermentation technology, lacking roots in traditional medicine systems like Ayurveda, TCM, or folk medicine.

Health Benefits

• Improves digestive comfort by reducing bloating, gas, and normalizing stool frequency/consistency (demonstrated in 80-person RCT)
• Enhances gut barrier function by reducing intestinal permeability markers like zonulin and endotoxins (moderate evidence from clinical trials)
• Provides prebiotic effects by increasing beneficial bacteria like lactobacilli and bifidobacteria while reducing pathogens (supported by SHIME model studies)
• Reduces intestinal inflammation through decreased pro-inflammatory cytokines (preliminary evidence from in vitro Caco-2/THP-1 cocultures)
• Supports mucosal defense in constipated populations (demonstrated in PMC10895063 clinical trial)

How It Works

EpiCor PET contains beta-1,3/1,6-glucans that bind to Dectin-1 and TLR-2 receptors on intestinal epithelial and dendritic cells, modulating NFκB signaling to reduce pro-inflammatory cytokine release while supporting secretory IgA production. Its mannan oligosaccharides competitively inhibit pathogen adhesion to intestinal mucosa and serve as fermentable substrate for Lactobacillus and Bifidobacterium species, increasing short-chain fatty acid (SCFA) production including butyrate, which upregulates tight junction proteins claudin-1 and occludin. Additionally, its polyphenol and antioxidant fractions reduce oxidative stress markers, indirectly lowering zonulin secretion and endotoxin translocation across the gut epithelium.

Scientific Research

Key clinical evidence includes a randomized, double-blind, placebo-controlled trial (NCT03051399) with 80 adults showing improvements in digestive comfort and gut barrier function at 500mg/day for 6 weeks. Additional RCTs (PMC5584023, PMC10895063) demonstrated reduced GI symptoms and improved bowel movements in adults with digestive discomfort.

Clinical Summary

An 80-person randomized controlled trial demonstrated that EpiCor fermentate significantly reduced bloating, normalized stool frequency, and improved overall digestive comfort compared to placebo over a 4-week intervention period. Clinical trials in humans and translational animal studies have shown measurable reductions in zonulin (a tight junction regulator) and circulating lipopolysaccharide (LPS) endotoxin levels, indicating improved intestinal barrier integrity. Prebiotic efficacy has been confirmed through fecal microbiome analyses showing increased Bifidobacterium and Lactobacillus counts alongside elevated fecal SCFA concentrations. Evidence for the pet-specific formulation (EpiCor PET) is primarily extrapolated from human trials and in vitro fermentation studies; dedicated large-scale RCTs in dogs and cats remain limited.

Nutritional Profile

EpiCor PET is a whole-food fermentate derived from Saccharomyces cerevisiae yeast, produced through a proprietary fermentation and drying process. Key bioactive components include: beta-glucans (approximately 20-30% of dry weight, primarily 1,3/1,6-linked), mannoproteins and mannan-oligosaccharides (~25-35%), and a complex array of metabolites generated during fermentation. Protein content is approximately 35-45% of dry weight, comprising yeast structural proteins and peptides with moderate bioavailability due to cell wall processing. Nucleotides and nucleosides (including adenosine, uridine) are present at measurable concentrations contributing to immune signaling. B-vitamins are naturally present including B1 (thiamine), B2 (riboflavin), B3 (niacin), B6, and folate at low but biologically relevant concentrations inherent to yeast biomass. Minerals include zinc (~3-5 mg/100g), selenium (variable, strain-dependent), iron, and magnesium in organically bound forms with moderate bioavailability. Bioactive antioxidant compounds include glutathione, superoxide dismutase (SOD), and phenolic metabolites generated during fermentation. Short-chain fatty acid precursors and organic acids (including acetic acid, lactic acid) from fermentation are present. Dietary fiber equivalents from beta-glucans and chitin in the cell wall contribute approximately 15-25% of dry weight. Typical serving doses range from 500 mg to 1 g/day in studied formulations, with bioavailability of beta-glucans and fermentation metabolites enhanced compared to non-fermented yeast due to partial cell wall disruption during processing.

Preparation & Dosage

Clinically studied dose is 500 mg/day as a powder in single servings, taken for 6 weeks or longer for gut comfort and barrier function support. The product is used as a non-standardized dried fermentate powder without extract forms. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Probiotics, Prebiotics, L-Glutamine, Digestive Enzymes, Zinc Carnosine

Safety & Interactions

EpiCor PET is generally regarded as safe for dogs and cats, with no serious adverse events reported in available studies at recommended supplemental doses, typically ranging from 40–500 mg/day depending on animal body weight. Because it stimulates immune pathways via TLR-2 and Dectin-1 signaling, caution is theoretically warranted in pets receiving immunosuppressive medications such as cyclosporine or corticosteroids, as enhanced immune activation could partially counteract drug effects. Pets with confirmed yeast allergies (Saccharomyces cerevisiae) should be evaluated by a veterinarian before use, as the fermentate is yeast-derived, though the fermentation process substantially alters the antigenic profile. No reproductive or developmental toxicity data are available for pregnant or lactating animals, so use in these populations should be guided by veterinary judgment.